Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 517 entries
View as:

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05088343 Org: User:
Start: 09/07/20 End: 01/16/21 Due: 01/16/22

The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT04554043 Org: User:
Start: 09/11/20 End: 09/28/21 Due: 09/28/22

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT06346925 Org: User:
Start: 04/30/24 End: 07/31/24 Due: 07/31/25

Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia

Phase: N/A Priority: Normal
NCT ID: NCT04867343 Org: User:
Start: 06/07/21 End: 08/15/23 Due: 08/15/24

A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05375305 Org: User:
Start: 05/11/22 End: 10/19/23 Due: 10/19/24

The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02361138 Org: User:
Start: 12/31/13 End: 05/31/14 Due: 05/31/15

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT04414852 Org: User:
Start: 06/05/20 End: 04/30/21 Due: 04/30/22

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03481998 Org: User:
Start: 03/22/18 End: 07/30/22 Due: 07/30/23

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Phase: N/A Priority: Normal
NCT ID: NCT04794738 Org: User:
Start: 04/18/21 End: 10/30/21 Due: 10/30/22

Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05685420 Org: User:
Start: 01/23/23 End: 06/30/24 Due: 06/30/25

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03710265 Org: User:
Start: 11/20/18 End: 12/31/22 Due: 12/31/23

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02671513 Org: User:
Start: 01/31/16 End: 04/30/17 Due: 04/30/18

A Food Effect Study of Apatinib Mesylate in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04341090 Org: User:
Start: 05/13/20 End: 07/06/20 Due: 07/06/21

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03083041 Org: User:
Start: 03/22/17 End: 05/20/22 Due: 05/20/23

Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02361112 Org: User:
Start: 08/31/14 End: 12/31/16 Due: 12/31/17

A Food Effect Study of FMTN on Healthy Chinese Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04616716 Org: User:
Start: 05/06/20 End: 10/20/20 Due: 10/20/21

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03666728 Org: User:
Start: 11/30/18 End: 03/11/20 Due: 03/11/21

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04457180 Org: User:
Start: 11/16/20 End: 06/19/21 Due: 06/19/22

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04718740 Org: User:
Start: 06/25/21 End: 07/15/23 Due: 07/15/24

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06254742 Org: User:
Start: 02/29/24 End: 06/30/24 Due: 06/30/25

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase: N/A Priority: Normal
NCT ID: NCT06123494 Org: User:
Start: 01/09/24 End: 06/30/27 Due: 06/30/28

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04906993 Org: User:
Start: 07/23/21 End: 04/30/25 Due: 04/30/26

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03732508 Org: User:
Start: 11/30/18 End: 10/31/20 Due: 10/31/21

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT04443751 Org: User:
Start: 09/10/20 End: 02/28/23 Due: 02/28/24

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Phase: N/A Priority: Normal
NCT ID: NCT05016323 Org: User:
Start: 09/09/21 End: 05/31/24 Due: 05/31/25